Related Experiment Video

Updated: Feb 23, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K

Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery

Liping Deng1, Jian Dong, Wei Wang

  • 1Department of Pharmacology, Chemistry and Chemical Engineering Institute, Shaoxing University, Shaoxing, Zhejiang 312000, China. wwdlp@126.com

Mini Reviews in Medicinal Chemistry
|February 5, 2013
PubMed

Insights

Cantharidin analogues show enhanced antitumor activity with reduced toxicity compared to the natural toxin. This review highlights structure-activity relationships and design principles for developing novel anti-cancer drug candidates.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Cantharidin (CTD) is a natural toxin that inhibits protein phosphatases 1 (PP1) and 2A (PP2A), showing activity against various cancer cells, particularly hepatocellular carcinoma.
  • The clinical use of CTD is limited due to its significant cytotoxicity.

Purpose of the Study:

  • To review structure-activity relationships of Cantharidin analogues, including norcantharidin (NCTD) and cantharimides.
  • To outline recent advances in designing CTD-based inhibitors for anti-cancer drug development.
  • To discuss strategies for mitigating CTD's cytotoxicity using drug carriers.

Main Methods:

  • Review of existing literature on Cantharidin analogues and their biological activities.
  • Analysis of structure-activity relationships (SAR) for CTD derivatives.
  • Discussion of drug design principles and advancements in anti-cancer drug screening.

Main Results:

  • Cantharidin analogues exhibit improved antitumor efficacy and reduced cytotoxicity compared to CTD.
  • Novel CTD-based inhibitors have been designed with enhanced anti-cancer properties.
  • Drug delivery systems are being explored to reduce the toxicity of CTD and its derivatives.

Conclusions:

  • Cantharidin analogues represent promising candidates for anti-cancer drug development.
  • Rational design of protein phosphatase inhibitors can be advanced by understanding protein-inhibitor interactions and structural biology.
  • Further research into CTD analogues and drug delivery systems holds potential for effective cancer therapies.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K